Changmao Biochemical FY26 H1 net loss narrows to RMB 5.09 million; revenue rises 6.3% to RMB 289.55 million

• Changmao Biochemical posted a net loss attributable to shareholders of RMB 4.93 million, narrowing 81% year over year.
• Revenue rose 6.3% to RMB 289.55 million, helped by product-structure adjustments and higher output of higher-margin products.
• Gross profit climbed to RMB 42.54 million from RMB 13.15 million, lifting gross margin to 14.7% from 4.8%.
• Operating profit swung to RMB 6.01 million from an operating loss of RMB 19.49 million.
• Management said it recorded a profit in the second quarter, citing improved sales traction for Changmao Dalian’s phase-two products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Changmao Biochemical Engineering Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260901-12312799), on September 01, 2026, and is solely responsible for the information contained therein.